IDEAYA Biosciences, Inc. Common Stock IDYA
$25.56
-2.33%
at last close
Analyst Consensus
- Consensus Rating
- Buy (11 Buy · 1 Hold · 0 Sell)
- Average Price Target
- $49.55
- Implied Upside
- +93.8%
- Price Target Range
- $35.00 – $66.00
- Analysts (12 mo)
- 12
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| 2026-11-17 | RBC CapitalLeonid Timashev |
Reiterates | Outperform | $45 |
| 2026-11-10 | MizuhoGraig Suvannavejh |
Maintains | Outperform | $44 → $39 |
| 2026-11-05 | CitigroupYigal Nochomovitz |
Maintains | Buy | $65 → $66 |
| 2026-11-04 | RBC CapitalLeonid Timashev |
Maintains | Outperform | $48 → $45 |
| 2026-11-04 | Truist SecuritiesGregory Renza |
Reiterates | Buy | $59 → $57 |
| 2026-11-04 | GuggenheimPaul Jeng |
Maintains | Buy | $57 → $52 |
| 2026-11-04 | WedbushRobert Driscoll |
Maintains | Outperform | $60 → $63 |
| 2026-10-16 | William BlairAlethia Young |
Initiates coverage on | Outperform | — |
| 2026-10-14 | StifelLaura Prendergast |
Initiates coverage on | Buy | $48 |
| 2026-09-09 | GuggenheimPaul Jeng |
Maintains | Buy | $54 → $57 |
| 2026-09-01 | CitizensSilvan Turkcan |
Reiterates | Market outperform | $42 |
| 2026-08-05 | Truist SecuritiesGregory Renza |
Maintains | Buy | $63 → $59 |
| 2026-08-05 | WedbushRobert Driscoll |
Maintains | Outperform | $58 → $60 |
| 2026-07-07 | RBC CapitalLeonid Timashev |
Maintains | Outperform | $53 → $48 |
| 2026-07-07 | Truist SecuritiesGregory Renza |
Maintains | Buy | $65 → $63 |
| 2026-06-12 | WedbushRobert Driscoll |
Reiterates | Outperform | $58 |
| 2026-06-02 | WedbushRobert Driscoll |
Reiterates | Outperform | $58 |
| 2026-05-07 | MizuhoGraig Suvannavejh |
Maintains | Outperform | $52 → $50 |
| 2026-04-14 | Goldman SachsCorinne Jenkins |
Maintains | Neutral | $31 → $35 |
| 2026-04-14 | Wells FargoEva Fortea Verdejo |
Maintains | Overweight | $44 → $48 |
| 2026-04-14 | RBC CapitalLeonid Timashev |
Maintains | Outperform | $49 → $53 |
| 2026-04-14 | WedbushRobert Driscoll |
Maintains | Outperform | $52 → $58 |
| 2026-04-14 | GuggenheimPaul Jeng |
Maintains | Buy | $50 → $54 |
| 2026-03-31 | WedbushRobert Driscoll |
Reiterates | Outperform | $52 |
| 2026-02-19 | CitigroupYigal Nochomovitz |
Maintains | Buy | $64 → $65 |
| 2026-02-18 | RBC CapitalLeonid Timashev |
Reiterates | Outperform | $49 |
| 2026-02-18 | GuggenheimPaul Jeng |
Reiterates | Buy | $50 |
| 2026-02-18 | WedbushRobert Driscoll |
Maintains | Outperform | $49 → $52 |
| 2026-01-21 | RBC CapitalLeonid Timashev |
Maintains | Outperform | $41 → $45 |
| 2026-01-07 | UBSMichael Yee |
Assumes | Buy | $50 |
Ratings and price targets reflect each firm's most recent published action. Consensus combines the latest call from every covering firm over the past 12 months; price targets are typically 12-month horizons.
Key Stats
- Last Close
- $25.56
- Market Cap
- $2.47 billion
- 52-Week Range
- $25.46 – $42.68
- Average Volume
- 1.08 million shs
Data is delayed and provided for informational purposes only. Not investment advice. See our disclaimer.
